508 filings
8-K
ALNY
Alnylam Pharmaceuticals Inc
20 May 24
Submission of Matters to a Vote of Security Holders
4:34pm
10-Q
2024 Q1
ALNY
Alnylam Pharmaceuticals Inc
Quarterly report
2 May 24
8:21am
8-K
ALNY
Alnylam Pharmaceuticals Inc
2 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
8:11am
ARS
2023 FY
ALNY
Alnylam Pharmaceuticals Inc
1 Apr 24
Annual report to shareholders
4:37pm
DEFA14A
ALNY
Alnylam Pharmaceuticals Inc
1 Apr 24
Additional proxy soliciting materials
4:34pm
8-K
f9m4f dwv
4 Mar 24
Departure of Directors or Certain Officers
4:33pm
8-K
6pp3d4kqv4dqlkp nh
15 Feb 24
Results of Operations and Financial Condition
8:10am
8-K
oyoqbmvj
19 Jan 24
Departure of Directors or Certain Officers
4:31pm
8-K
lphiy
8 Jan 24
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
7:00am
8-K
1nszxs3r o39iw
2 Nov 23
Results of Operations and Financial Condition
8:10am
8-K
nflq2d9le5 b519r
10 Oct 23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the
7:30am
8-K
0jlw hoe2
28 Sep 23
Departure of Directors or Certain Officers
5:00pm
8-K
wfd8s32 uupi17g
3 Aug 23
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8:10am
8-K
rj494rick6de7f
26 Jul 23
Entry into a Material Definitive Agreement
5:15pm
8-K
6mx8o1c5qyo2 b0t
30 Jun 23
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR
9:03am
8-K
22rsevoav69ae
23 May 23
Submission of Matters to a Vote of Security Holders
4:30pm